Enfusion (NYSE:ENFN) Lowered to Sell at Zacks Investment Research

Enfusion (NYSE:ENFNGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday, Zacks.com reports.

According to Zacks, “Enfusion Inc. is a provider of cloud-based investment management software and services. Through its software, analytics and middle/back-office managed services, it creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility and powering growth. Enfusion Inc. is based in NEW YORK. “

ENFN has been the subject of several other reports. Morgan Stanley decreased their price objective on shares of Enfusion from $22.00 to $18.00 and set an “equal weight” rating for the company in a research note on Friday, March 25th. Credit Suisse Group decreased their price objective on shares of Enfusion from $25.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, March 25th. The Goldman Sachs Group decreased their price objective on shares of Enfusion from $24.00 to $15.00 and set a “neutral” rating for the company in a research note on Wednesday, March 16th. Piper Sandler decreased their price objective on shares of Enfusion from $26.00 to $20.00 in a research note on Friday, March 25th. Finally, Stifel Nicolaus decreased their price objective on shares of Enfusion from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, March 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Enfusion presently has an average rating of “Hold” and an average target price of $18.67.

Enfusion stock traded down $0.01 during trading on Monday, reaching $11.04. The company had a trading volume of 255,728 shares, compared to its average volume of 285,770. Enfusion has a 12-month low of $7.80 and a 12-month high of $23.21. The stock’s 50 day moving average price is $11.46 and its two-hundred day moving average price is $14.82.

Enfusion (NYSE:ENFNGet Rating) last released its earnings results on Thursday, March 24th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.51. The company had revenue of $31.85 million during the quarter, compared to analysts’ expectations of $30.52 million. Sell-side analysts predict that Enfusion will post 0.1 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. acquired a new position in shares of Enfusion during the fourth quarter worth $29,000. Legal & General Group Plc acquired a new stake in Enfusion in the fourth quarter valued at $44,000. Allspring Global Investments Holdings LLC acquired a new stake in Enfusion in the first quarter valued at $65,000. Citigroup Inc. acquired a new stake in Enfusion in the fourth quarter valued at $120,000. Finally, Metropolitan Life Insurance Co NY acquired a new stake in Enfusion in the fourth quarter valued at $142,000. 61.18% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Company Profile (Get Rating)

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.

Featured Stories

Get a free copy of the Zacks research report on Enfusion (ENFN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Enfusion (NYSE:ENFN)

Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.